Literature DB >> 31364359

The Role of Protein Thermodynamics and Primary Structure in Fibrillogenesis of Variable Domains from Immunoglobulin Light Chains.

Enrico Rennella1, Gareth J Morgan2,3, Nicholas Yan2, Jeffery W Kelly2, Lewis E Kay1,4.   

Abstract

Immunoglobulin light-chain amyloidosis is a protein aggregation disease that leads to proteinaceous deposits in a variety of organs in the body and, if untreated, ultimately results in death. The mechanisms by which light-chain aggregation occurs are not well understood. Here we have used solution NMR spectroscopy and biophysical studies to probe immunoglobulin variable domain λV6-57 VL aggregation, a process that appears to drive the degenerative phenotypes in amyloidosis patients. Our results establish that aggregation proceeds via the unfolded state. We identify, through NMR relaxation experiments recorded on the unfolded domain ensemble, a series of hotspots that could be involved in the initial phases of aggregate formation. Mutational analysis of these hotspots reveals that the region that includes K16-R24 is particularly aggregation prone. Notably, this region includes the site of the R24G substitution, a mutation that is found in variable domains of λ light-chain deposits in 25% of patients. The R24G λV6-57 VL domain aggregates more rapidly than would be expected on the basis of thermodynamic stability alone, while substitutions in many of the aggregation-prone regions significantly slow down fibril formation.

Entities:  

Year:  2019        PMID: 31364359      PMCID: PMC6850217          DOI: 10.1021/jacs.9b05499

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  55 in total

1.  Low-populated folding intermediates of Fyn SH3 characterized by relaxation dispersion NMR.

Authors:  Dmitry M Korzhnev; Xavier Salvatella; Michele Vendruscolo; Ariel A Di Nardo; Alan R Davidson; Christopher M Dobson; Lewis E Kay
Journal:  Nature       Date:  2004-07-29       Impact factor: 49.962

2.  An improved 15N relaxation dispersion experiment for the measurement of millisecond time-scale dynamics in proteins.

Authors:  D Flemming Hansen; Pramodh Vallurupalli; Lewis E Kay
Journal:  J Phys Chem B       Date:  2007-11-15       Impact factor: 2.991

Review 3.  AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.

Authors:  Rodney H Falk; Kevin M Alexander; Ronglih Liao; Sharmila Dorbala
Journal:  J Am Coll Cardiol       Date:  2016-09-20       Impact factor: 24.094

4.  Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity.

Authors:  V Bellotti; G Merlini; E Bucciarelli; V Perfetti; S Quaglini; E Ascari
Journal:  Br J Haematol       Date:  1990-01       Impact factor: 6.998

5.  Protein folding intermediates: native-state hydrogen exchange.

Authors:  Y Bai; T R Sosnick; L Mayne; S W Englander
Journal:  Science       Date:  1995-07-14       Impact factor: 47.728

6.  Self-Assembly of Human Profilin-1 Detected by Carr-Purcell-Meiboom-Gill Nuclear Magnetic Resonance (CPMG NMR) Spectroscopy.

Authors:  Enrico Rennella; Ashok Sekhar; Lewis E Kay
Journal:  Biochemistry       Date:  2017-01-20       Impact factor: 3.162

7.  Pitfalls of molecular replacement: the structure determination of an immunoglobulin light-chain dimer.

Authors:  D B Huang; C Ainsworth; A Solomon; M Schiffer
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1996-11-01

8.  Thermodynamic and fibril formation studies of full length immunoglobulin light chain AL-09 and its germline protein using scan rate dependent thermal unfolding.

Authors:  Luis M Blancas-Mejía; Timothy J Horn; Marta Marin-Argany; Matthew Auton; Alexander Tischer; Marina Ramirez-Alvarado
Journal:  Biophys Chem       Date:  2015-08-04       Impact factor: 2.352

9.  Incidence and survival in non-hereditary amyloidosis in Sweden.

Authors:  Kari Hemminki; Xinjun Li; Asta Försti; Jan Sundquist; Kristina Sundquist
Journal:  BMC Public Health       Date:  2012-11-13       Impact factor: 3.295

10.  MAK33 antibody light chain amyloid fibrils are similar to oligomeric precursors.

Authors:  Manuel Hora; Riddhiman Sarkar; Vanessa Morris; Kai Xue; Elke Prade; Emma Harding; Johannes Buchner; Bernd Reif
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

View more
  5 in total

1.  A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation.

Authors:  Daniele Peterle; Elena S Klimtchuk; Thomas E Wales; Florian Georgescauld; Lawreen H Connors; John R Engen; Olga Gursky
Journal:  J Mol Biol       Date:  2021-10-19       Impact factor: 5.469

2.  Mechanism of misfolding of the human prion protein revealed by a pathological mutation.

Authors:  Máximo Sanz-Hernández; Joseph D Barritt; Jens Sobek; Simone Hornemann; Adriano Aguzzi; Alfonso De Simone
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-23       Impact factor: 12.779

3.  The effect of mutation on an aggregation-prone protein: An in vivo, in vitro, and in silico analysis.

Authors:  N Guthertz; R van der Kant; R M Martinez; Y Xu; C Trinh; B I Iorga; F Rousseau; J Schymkowitz; D J Brockwell; S E Radford
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-25       Impact factor: 12.779

4.  An in vivo platform to select and evolve aggregation-resistant proteins.

Authors:  Jessica S Ebo; Janet C Saunders; Paul W A Devine; Alice M Gordon; Amy S Warwick; Bob Schiffrin; Stacey E Chin; Elizabeth England; James D Button; Christopher Lloyd; Nicholas J Bond; Alison E Ashcroft; Sheena E Radford; David C Lowe; David J Brockwell
Journal:  Nat Commun       Date:  2020-04-14       Impact factor: 14.919

5.  Cu(II) Binding Increases the Soluble Toxicity of Amyloidogenic Light Chains.

Authors:  Rosaria Russo; Margherita Romeo; Tim Schulte; Martina Maritan; Luca Oberti; Maria Monica Barzago; Alberto Barbiroli; Carlo Pappone; Luigi Anastasia; Giovanni Palladini; Luisa Diomede; Stefano Ricagno
Journal:  Int J Mol Sci       Date:  2022-01-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.